Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDX NASDAQ:INVA NASDAQ:LXRX NASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$22.87+0.4%$22.46$14.40▼$47.00$1.51B1.191.57 million shs1.14 million shsINVAInnoviva$20.48-2.1%$19.58$16.67▼$22.00$1.32B0.47743,277 shs950,155 shsLXRXLexicon Pharmaceuticals$1.09+1.9%$1.10$0.28▼$2.18$388.84M1.261.84 million shs1.78 million shsMNKDMannKind$5.54+3.7%$4.00$3.38▼$7.63$1.64B1.025.09 million shs6.76 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics+0.40%+3.58%+6.67%+7.12%-48.65%INVAInnoviva-2.10%+0.24%+12.24%-5.10%+4.01%LXRXLexicon Pharmaceuticals+1.87%-0.91%-5.22%+41.56%-33.13%MNKDMannKind+3.75%+20.70%+60.12%+26.48%-9.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$22.87+0.4%$22.46$14.40▼$47.00$1.51B1.191.57 million shs1.14 million shsINVAInnoviva$20.48-2.1%$19.58$16.67▼$22.00$1.32B0.47743,277 shs950,155 shsLXRXLexicon Pharmaceuticals$1.09+1.9%$1.10$0.28▼$2.18$388.84M1.261.84 million shs1.78 million shsMNKDMannKind$5.54+3.7%$4.00$3.38▼$7.63$1.64B1.025.09 million shs6.76 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics+0.40%+3.58%+6.67%+7.12%-48.65%INVAInnoviva-2.10%+0.24%+12.24%-5.10%+4.01%LXRXLexicon Pharmaceuticals+1.87%-0.91%-5.22%+41.56%-33.13%MNKDMannKind+3.75%+20.70%+60.12%+26.48%-9.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.78Moderate Buy$46.67104.05% UpsideINVAInnoviva 3.00Buy$42.75108.74% UpsideLXRXLexicon Pharmaceuticals 2.50Moderate Buy$3.23195.87% UpsideMNKDMannKind 3.25Buy$10.7193.40% UpsideCurrent Analyst Ratings BreakdownLatest LXRX, CLDX, MNKD, and INVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025MNKDMannKindOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $15.009/3/2025MNKDMannKindWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$9.00 ➝ $10.009/2/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.009/2/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $11.008/26/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $8.008/25/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.008/20/2025CLDXCelldex TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$44.00 ➝ $38.008/20/2025CLDXCelldex TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$56.00 ➝ $48.008/20/2025CLDXCelldex TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$64.00 ➝ $62.008/20/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $42.008/11/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$7.02M216.35N/AN/A$11.26 per share2.03INVAInnoviva$358.71M3.60$3.35 per share6.11$11.03 per share1.86LXRXLexicon Pharmaceuticals$31.08M12.74N/AN/A$0.40 per share2.73MNKDMannKind$285.50M5.95$0.14 per share38.48($0.29) per share-19.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$157.86M-$3.01N/AN/AN/A-3,446.88%-27.61%-26.20%11/5/2025 (Estimated)INVAInnoviva$23.39M$0.3166.0713.21N/A10.44%18.67%9.92%11/5/2025 (Estimated)LXRXLexicon Pharmaceuticals-$200.40M-$0.33N/AN/AN/A-206.43%-83.63%-42.22%11/11/2025 (Estimated)MNKDMannKind$27.59M$0.1150.3724.09N/A10.87%-32.60%7.81%11/6/2025 (Estimated)Latest LXRX, CLDX, MNKD, and INVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CLDXCelldex Therapeutics-$0.86-$0.85+$0.01-$0.85$1.13 million$0.73 million8/6/2025Q2 2025INVAInnoviva$0.57$0.77+$0.20$0.77$87.10 million$100.28 million8/6/2025Q2 2025LXRXLexicon Pharmaceuticals-$0.08$0.01+$0.09$0.01$4.87 million$28.87 million8/6/2025Q2 2025MNKDMannKind$0.04$0.05+$0.01N/A$77.82 million$76.53 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A19.6719.67INVAInnoviva0.362.642.44LXRXLexicon Pharmaceuticals0.434.164.16MNKDMannKindN/A2.502.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/AINVAInnoviva99.12%LXRXLexicon Pharmaceuticals74.70%MNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics4.40%INVAInnoviva2.25%LXRXLexicon Pharmaceuticals13.90%MNKDMannKind2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15066.41 million63.49 millionOptionableINVAInnoviva10063.02 million61.60 millionOptionableLXRXLexicon Pharmaceuticals140363.40 million312.89 millionOptionableMNKDMannKind400306.83 million298.54 millionOptionableLXRX, CLDX, MNKD, and INVA HeadlinesRecent News About These CompaniesMannKind Corporation $MNKD Shares Sold by Northern Trust Corp2 hours ago | marketbeat.comWells Fargo & Company Forecasts Strong Price Appreciation for MannKind (NASDAQ:MNKD) StockSeptember 5 at 9:44 AM | marketbeat.comState of Wyoming Boosts Position in MannKind Corporation $MNKDSeptember 5 at 4:27 AM | marketbeat.comMannKind Corporation $MNKD Shares Bought by Trexquant Investment LPSeptember 5 at 4:27 AM | marketbeat.comWells Fargo & Company Issues Positive Forecast for MannKind (NASDAQ:MNKD) Stock PriceSeptember 5 at 3:21 AM | americanbankingnews.comHC Wainwright Has Positive View of MannKind FY2028 EarningsSeptember 5 at 2:05 AM | americanbankingnews.comMannKind (NASDAQ:MNKD) Shares Gap Up After Analyst UpgradeSeptember 4 at 12:58 PM | marketbeat.comHC Wainwright Issues Positive Forecast for MannKind (NASDAQ:MNKD) Stock PriceSeptember 4 at 12:33 PM | marketbeat.comInvestors Buy High Volume of Call Options on MannKind (NASDAQ:MNKD)September 4 at 10:51 AM | marketbeat.comMannKind (NASDAQ:MNKD) Price Target Raised to $11.00 at HC WainwrightSeptember 4 at 2:58 AM | americanbankingnews.comStock Traders Purchase High Volume of Call Options on MannKind (NASDAQ:MNKD)September 4 at 2:23 AM | americanbankingnews.comMannKind (NASDAQ:MNKD) Shares Gap Up on Analyst UpgradeSeptember 4 at 2:21 AM | americanbankingnews.comPositive TETON-2 Study Results Drive Buy Rating and Price Target Increase for MannKindSeptember 2, 2025 | tipranks.comUnited Therapeutics succeeds in late-stage trial for Tyvaso against lung disorderSeptember 2, 2025 | msn.comWellington Management Group LLP Reduces Stock Position in MannKind Corporation $MNKDSeptember 1, 2025 | marketbeat.comRussell Investments Group Ltd. Cuts Position in MannKind Corporation $MNKDSeptember 1, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Stock Price Up 10.4% on Analyst UpgradeAugust 29, 2025 | marketbeat.comInvesco Ltd. Grows Position in MannKind Corporation $MNKDAugust 29, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Shares Up 10.4% Following Analyst UpgradeAugust 29, 2025 | americanbankingnews.comMannKind to Present at Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comMannKind (NASDAQ:MNKD) Stock Price Down 5.2% - Here's What HappenedAugust 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLXRX, CLDX, MNKD, and INVA Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$22.87 +0.09 (+0.40%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$22.86 -0.01 (-0.02%) As of 09/5/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Innoviva NASDAQ:INVA$20.48 -0.44 (-2.10%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$20.48 0.00 (0.00%) As of 09/5/2025 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Lexicon Pharmaceuticals NASDAQ:LXRX$1.09 +0.02 (+1.87%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.06 -0.03 (-2.84%) As of 09/5/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.MannKind NASDAQ:MNKD$5.54 +0.20 (+3.75%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$5.54 0.00 (-0.09%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
